Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Driven Fractional Flow Reserve Assessment: Technical Foundations, Clinical Insights, and Future Directions.

Medicina (Kaunas, Lithuania)·2026
Same author

Evaluation of ePLAR, the echocardiographic pulmonary to left atrial ratio, in a large cohort with pulmonary hypertension.

European heart journal open·2026
Same author

Benzothiazole Derivatives as Dual Modulators of PGE2 and GABAergic Signaling in Skeletal Muscle.

bioRxiv : the preprint server for biology·2026
Same author

Clinical outcomes and impact of aortic valve replacement in concordant vs discordant high-gradient aortic stenosis.

American heart journal·2026
Same author

Synthesis and characterization of a novel phosphatidylinositol 5-phosphate (PI(5)P) photoaffinity probe.

RSC chemical biology·2026
Same author

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Journal of hematology & oncology·2026

Related Experiment Video

Updated: Jun 6, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.5K

Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis.

Ahmed Sayed1,2, Mohamed ElRefaei1, Kamal Awad3

  • 1Faculty of Medicine, Ain Shams University, Cairo, Egypt.

JAMA Network Open
|November 27, 2024
PubMed
Summary

Heart failure (HF) hospitalizations are underreported in trials. Significant reductions in HF hospitalizations are needed to infer any decrease in all-cause hospitalizations, highlighting a critical gap in reporting for heart failure research.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

Related Experiment Videos

Last Updated: Jun 6, 2025

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.5K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

Area of Science:

  • Cardiology
  • Clinical Trials
  • Health Services Research

Background:

  • Heart failure (HF) hospitalization is a key endpoint in HF clinical trials.
  • The relationship between HF hospitalizations and all-cause hospitalizations, including reporting practices, remains understudied.

Purpose of the Study:

  • To determine the ratio of HF to all-cause hospitalizations.
  • To assess the correlation between treatment effects on HF hospitalization and all-cause hospitalization.
  • To evaluate the frequency of reporting all-cause hospitalization alongside HF hospitalization in randomized clinical trials (RCTs).

Main Methods:

  • A systematic search of PubMed for HF RCTs published in leading medical journals was conducted.
  • Data extraction followed PRISMA guidelines, focusing on baseline characteristics and hospitalization outcomes.
  • Hierarchical Bayesian models were used to evaluate the association between treatment effects on HF and all-cause hospitalizations.

Main Results:

  • Of 113 trials (261,068 patients), 53.1% reported all-cause hospitalization.
  • The weighted median ratio of HF to all-cause hospitalizations was 45.9%.
  • Reported treatment effects on HF and all-cause hospitalizations were highly correlated (R²=90.1%), but substantial reductions in HF events were needed to infer reductions in all-cause events.

Conclusions:

  • All-cause hospitalization is underreported in HF trials despite its significant burden.
  • Clinically relevant reductions in all-cause hospitalizations cannot be inferred without large observed reductions in HF hospitalizations.
  • This highlights a need for improved reporting standards in heart failure research.